Biotech Stock News 3/20

$Annovis Bio (ANVS.US)$ 22% Ph2/3 data reporting update
$Taysha Gene Therapies (TSHA.US)$ 21% FY 2023 results
$TFF Pharmaceuticals (TFFP.US)$ 14% Clinical programs update
$Jaguar Health (JAGX.US)$ 14% Crofelemer commercialization
$Acelyrin (SLRN.US)$ 4% Ph1/2 positive data
$Delcath Systems (DCTH.US)$ 3% Closes $7M private placement
$Sellas Life Sciences (SLS.US)$ 0% Closes $20M offering & private placement
$Immunic (IMUX.US)$ 1% Patent notice of allowance
$Nurix Therapeutics (NRIX.US)$ 0% Presentation @ ACS
$Achieve Life (ACHV.US)$ 0% Present ORCA data @ SRNT '24
$Bristol-Myers Squibb (BMY.US)$ 0% Ph3 CheckMate -9DW data
$Kazia Therapeutics (KZIA.US)$ 0% EVT801 progress update
$Cabaletta Bio (CABA.US)$ 0% Granted ODD

$XOMA Corp (XOMA.US)$ -1% M&A update
$NGM Biopharmaceuticals (NGM.US)$ -1% Presentations @ AACR '24
$Alnylam Pharmaceuticals (ALNY.US)$ -1% KARDIA-2 trial investor event
$Tonix Pharmaceuticals (TNXP.US)$ -3% Tonmya launch & manuf. update
$Valneva (VALN.US)$ -5% FY 2023 results
$Celularity (CELU.US)$ -6% Submits ODD request for PDA-002
$Entera Bio (ENTX.US)$ -7% GLP-2 tablet PK data
$Moleculin Biotech (MBRX.US)$ -14% Reverse stock split
$EVFMD -16% Improved rebate for PHEXXI
$Aquestive Therapeutics (AQST.US)$ -17% $75M public offering @ $4.50/sh
$Endo International (ENDPQ.US)$ -33% Reorganization plan confirmation